Abstract 21P
Background
CRPC patients (pts) with loss-of-function alterations in genes associated with homologous recombination (HR) can derive benefit from both PARPi and PlCh. Cross-resistance between these agents is well recognized in other tumour types and evidence of ‘reversion’ mutations in HR genes is emerging. Yet, optimal treatment sequence and data on cross-resistance in CRPC is lacking.
Methods
In this retrospective pre-planned single-centre study we describe intra-patient responses to PlCh and PARPi, assessed by the order of these HR-deficiency-targeting-agents (HRDtA; PARPi→PlCh or PlCh→PARPi). All pts were treated with both PlCh and PARPi, but agents were not necessarily given directly sequential.
Results
All 28 CRPC pts were metastatic and HR deficient, mostly due to BRCA2 inactivation (79%). Sixteen pts received PARPi→PlCh and 12 PlCh→PARPi. Pts with PlCh→PARPi had a significant shorter time to CRPC (median 10 vs. 18 months, P=0.040) and were significantly more often synchronous metastatic (92% vs. 44%, P=0.016). Progression-free survival (PFS) on the initial HRDtA was longer than the PFS on the subsequent HRDtA (median 5.3 versus 3.4 months, P=0.016). The median PFS on PARPi, given as subsequent HRDtA, was 0.9 months shorter than when administered first. For PlCh the PFS was 3.6 months shorter as subsequent HRDtA than as initial. Of the PARPi→PlCh pts, 6/16 (38%) had a >50% PSA decline to PlCh and 2/8 (25%) evaluable pts had a radiographic response to PlCh. In the PlCh→PARPi group, 6/10 (60%) evaluable pts had a >50% PSA decline to PARPi and 5/9 (56%) a radiographic response to PARPi. In total, 12/26 (46%) had a >50% PSA decline and 7/17 (41%) a radiographic response to a subsequent HRDtA. Overall survival from CRPC did not significantly differ depending on the order of HRDtA (PARPi→PlCh 45 months vs. PlCh→PARPi 33 months, hazard ratio 1.42, P=0.401).
Conclusions
This study suggests cross-resistance between PARPi and PlCh in HR deficient CRPC pts. PlCh appears to induce less cross-resistance to PARPi than vice versa. Still, >40% of the cohort is sensitive to a subsequent HRDtA. Serial assessment of (liquid) biopsies is warranted to unravel the mechanisms defining cross-resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Radboud University Medical Center, Nijmegen, The Netherlands.
Funding
Has not received any funding.
Disclosure
I.M. Van Oort: Financial Interests, Personal and Institutional, Advisory Role: Bayer, Astellas, Janssen, MSD/AstraZeneca; Financial Interests, Institutional, Research Grant: Astellas, Janssen, Bayer. J. Schalken: Financial Interests, Personal, Invited Speaker: Astellas, Bayer. N. Mehra: Financial Interests, Personal, Advisory Board: Pfizer, Roche, MSD, AstraZeneca, Astellas, JNJ; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Funding: Astellas, Pfizer; Financial Interests, Personal and Institutional, Funding: Janssen; Financial Interests, Institutional, Invited Speaker: BMS, Janssen; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Non-Financial Interests, Personal, Leadership Role, Head of the Prostate Cancer Working Group: Dutch Uro-Oncology Study Group; Non-Financial Interests, Personal, Principal Investigator, co-PI: Prospective Bladder Cancer Infrastructure (Netherlands); Non-Financial Interests, Personal, Leadership Role: Castration-resistant Prostate Cancer Registry. All other authors have declared no conflicts of interest.
Resources from the same session
25P - Relationship between aberrant methylation of CpG islands of microRNA gene promoters and changes in their expression in epithelial ovarian cancer
Presenter: Irina Pronina
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - 3MST: A potential workhorse in H2S signaling trimmed by microRNA-548 in breast cancer
Presenter: Alyaa Dawoud
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
Presenter: Yun Fan
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Deep learning approach for discovering new predictive histological features of immunotherapy response
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma
Presenter: Jinpeng Li
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Nomogram to predict survival of patients with unresectable melanoma receiving immune checkpoint inhibitors
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 checkpoint blockade in small cell lung cancer
Presenter: Evelyn Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Therapeutic vaccination with HPV-16 oncoproteins fused into a checkpoint modifier of early T cell activation protects against HPV-associated tumors in a preclinical model
Presenter: Susan Currie
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?
Presenter: Zhulin Yin
Session: Cocktail & Poster Display session
Resources:
Abstract
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract